Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug ‐Resistant Gram‐Negative Pathogens

AbstractCefiderocol (CFDC), (formerly S ‐649266), is a novel injectable siderophore cephalosporin developed by Shionogi& Co., Ltd., with potentin vitro activity against Gram ‐negative pathogens including multidrug‐resistant (MDR) Enterobacteriaceae and non‐fermenting organisms such asPseudomonas aeruginosa,Acinetobacter baumannii,Burkholderia cepacia, andStenotrophomonas maltophilia. Characterized by its siderophore catechol ‐moiety, CFDC uses a “trojan‐horse approach” to navigate through the bacterial periplasmic space thus, evading various beta‐lactam degrading enzymes and other mechanisms of resistance present in Gram‐negative bacteria. More specifically in carbapenem‐resistant Enterobacteriaceae, CFDC has been shown to have activity against extended spectrum beta‐lactamases (ESBLs), such as CTX‐type, SHV‐type, and TEM‐type, as well as the Ambler Classes of beta‐lactamases including Class A (KPC), Class B (NDM, IMP, VIM), Class C (AmpC), and Class D (OXA) (OXA‐24, OXA‐48, and OXA‐4 8‐like). In addition to the strong activity that CFDC has been shown to have against MDRP. aeruginosa, it has also displayed activity against the OXA ‐23, OXA‐24, and OXA‐51, beta‐lactamases commonly found in MDRA. baumannii. Cefiderocol was recently approved by the United States Food and Drug Administration (FDA) for use in complicated urinary tract infections (cUTI), including pyelonephritis, for use in patients 18 years or older with limited or ...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: REVIEW OF THERAPEUTICS Source Type: research